N6-methyladenosine (m6A) RNA methylation plays a pivotal role in immune responses and the onset and advancement of cancer. Nonetheless, the precise impact of m6A modification in lung adenocarcinoma (LUAD) and its associated tumor microenvironment (TME) remains to be fully elucidated. Here, we distinguished distinct m6A modification patterns within two separate LUAD cohorts using a set of 21 m6A regulators. The TME characteristics associated with these two patterns align with the immune-inflamed and immune-excluded phenotypes, respectively. We identified 2064 m6A-related genes, which were used as a basis to divide all LUAD samples into three distinct m6A gene clusters. We applied a scoring system to evaluate the m6A gene signature of the m6A modification pattern in individual patients. To authenticate the categorization significance of m6A modification patterns, we established a correlation between m6A score and TME infiltration profiling, tumor somatic mutations, and responses to immunotherapy. A high level of m6A modification may be associated with the aggressiveness and poor prognosis of LUAD. Further studies should investigate the mechanism of action of m6A regulators and m6A-related genes to improve the diagnosis and treatment of patients with LUAD.
LaviUFernandez-MuñozRDarnellJEJr.Content of N-6 methyl adenylic acid in heterogeneous nuclear and messenger RNA of HeLa cells.Nucleic Acids Res1977;4:63–9
2.
SunTWuRMingL. The role of m6A RNA methylation in cancer.Biomed Pharmacother2019;112:108613
3.
ZhuangZChenLMaoYZhengQLiHHuangYHuZJinY. Diagnostic, progressive and prognostic performance of m6A methylation RNA regulators in lung adenocarcinoma.Int J Biol Sci2020;16:1785–97
4.
MaYLiuXBiYWangTChenCWangYHanDCaoF. Alteration of N6-methyladenosine mRNA methylation in a human stem cell-derived cardiomyocyte model of tyrosine kinase inhibitor-induced cardiotoxicity.Front Cardiovasc Med2022;9:849175
5.
MaSChenCJiXLiuJZhouQWangGYuanWKanQSunZ. The interplay between m6A RNA methylation and noncoding RNA in cancer.J Hematol Oncol2019;12:121
6.
HuangHWengHChenJ. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer.Cancer Cell2020;37:270–88
7.
CokerHWeiGBrockdorffN. m6A modification of non-coding RNA and the control of mammalian gene expression.Biochim Biophys Acta Gene Regul Mech2019;1862:310–8
8.
LvWWangYZhaoCTanYXiongMYiYHeXRenYWuYZhangQ. Identification and validation of m6A-related lncRNA signature as potential predictive biomarkers in breast cancer.Front Oncol2021;11:745719
9.
NiXFXieQQZhaoJMXuYJJiMHuWWWuJWuCP. The hepatic microenvironment promotes lung adenocarcinoma cell proliferation, metastasis, and epithelial-mesenchymal transition via METTL3-mediated N6-methyladenosine modification of YAP1.Aging2021;13:4357–69
10.
ChenXXuMXuXZengKLiuXPanBLiCSunLQinJXuTHeBPanYSunHWangS. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.Mol Cancer2020;19:106
11.
ChenYPanCWangXXuDMaYHuJChenPXiangZRaoQHanX. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.Theranostics2021;11:7640–57
12.
TangRZhangYLiangCXuJMengQHuaJLiuJZhangBYuXShiS. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma.PeerJ2020;8:e9602
13.
XuSTangLDaiGLuoCLiuZ. Expression of m6A regulators correlated with immune microenvironment predicts therapeutic efficacy and prognosis in gliomas.Front Cell Dev Biol2020;8:594112
14.
ZhangYLiuXLiuLLiJHuQSunR. Expression and prognostic significance of m6A-related genes in lung adenocarcinoma.Med Sci Monit2020;26:e919644
15.
LiYGuJXuFZhuQChenYGeDLuC. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.Brief Bioinform2021;22:bbaa225
16.
LiNZhanX. Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.EPMA J2020;11:485–504
17.
National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial.J Thorac Oncol2019;14:1732–42
18.
Blake-CerdaMLozano-RuízFMaldonado-MagosFDe la Mata-MoyaDDíaz-GarcíaDLara-MejíaLZatarain-BarrónZLCuevas-GóngoraMFBarron-BarronFCorona-CruzJFCabrera-MirandaLArroyo-HernándezMGersonRArrietaO. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: a prospective phase 2 study.Lung Cancer2021;152:119–26
19.
Ruiz-CorderoRDevineWP. Targeted therapy and checkpoint immunotherapy in lung cancer.Surg Pathol Clin2020;13:17–33
20.
ZhengJZhaoZWanJGuoMWangYYangZLiZMingLQinZ. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.J Clin Lab Anal2021;35:e23951
21.
SunLLiuWKDuXWLiuXLLiGYaoYHanTLiWYGuJ. Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma.Ann Transl Med2020;8:751
22.
LinSXuHZhangANiYXuYMengTWangMLouM. Prognosis analysis and validation of m6A signature and tumor immune microenvironment in glioma.Front Oncol2020;10:541401
23.
AroraLPalD. Remodeling of stromal cells and immune landscape in microenvironment during tumor progression.Front Oncol2021;11:596798
24.
PanXZhengL. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment.Cell Mol Immunol2020;17:940–53
25.
BerraondoPSanmamedMFOchoaMCEtxeberriaIAznarMAPérez-GraciaJLRodríguez-RuizMEPonz-SarviseMCastañónEMeleroI. Cytokines in clinical cancer immunotherapy.Br J Cancer2019;120:6–15
26.
GaoRYeMLiuBWeiMMaDDongK. m6A modification: a double-edged sword in tumor development.Front Oncol2021;11:679367
27.
SongHSongJChengMZhengMWangTTianSFlavellRAZhuSLiHBDingCWeiHSunRPengHTianZ. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells.Nat Commun2021;12:5522
28.
MiaoTWYangDQChenFYZhuQChenX. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.Biosci Rep2022;42:BSR20212835
29.
LiZWeiJZhengHGanXSongMZhangYKongLZhangCYangJJinY. m6A regulator-mediated methylation modification patterns and tumor immune microenvironment in sarcoma.Aging2022;14:330–53
30.
CaoRMaBWangGXiongYTianYYuanL. Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer.Mol Ther Oncolytics2021;22:277–93
31.
LeekJTJohnsonWEParkerHSJaffeAEStoreyJD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments.Bioinformatics2012;28:882–3
32.
LuXYeKZouKChenJ. Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis.Oncol Rep2014;32:1845–52
33.
ZhangHMeltzerPDavisS. RCircos: an R package for Circos 2D track plots.BMC Bioinformatics2013;14:244
34.
LuoYSunXXiongJ. Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in ovarian cancer.Front Cell Dev Biol2022;9:794801
35.
WangLCaoHZhongYJiPChenF. The role of m6A regulator-mediated methylation modification and tumor microenvironment infiltration in glioblastoma multiforme.Front Cell Dev Biol2022;10:842835
36.
WilkersonMDHayesDN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.Bioinformatics2010;26:1572–3
37.
HänzelmannSCasteloRGuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data.BMC Bioinformatics2013;14:7
38.
LuoHYeMHuYWuMChengMZhuXHuangK. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.Aging2022;14:7824–50
39.
YuGWangLGHanYHeQY. clusterProfiler: an R package for comparing biological themes among gene clusters.OMICS2012;16:284–7
40.
MaCKangWYuLYangZDingT. AUNIP expression is correlated with immune infiltration and is a candidate diagnostic and prognostic biomarker for hepatocellular carcinoma and lung adenocarcinoma.Front Oncol2020;10:590006
41.
CharoentongPFinotelloFAngelovaMMayerCEfremovaMRiederDHacklHTrajanoskiZ. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.Cell Rep2017;18:248–62
42.
CaoRYuanLMaBWangGTianY. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA).Cancer Cell Int2020;20:276
43.
RitchieMEPhipsonBWuDHuYLawCWShiWSmythGK. limma powers differential expression analyses for RNA-sequencing and microarray studies.Nucleic Acids Res2015;43:e47
44.
ZhangXShiMChenTZhangB. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy.Mol Ther Nucleic Acids2020;22:298–309
45.
MayakondaALinDCAssenovYPlassCKoefflerHP. Maftools: efficient and comprehensive analysis of somatic variants in cancer.Genome Res2018;28:1747–56
46.
GivechianKBWnukKGarnerCBenzSGarbanHRabizadehSNiaziKSoon-ShiongP. Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples.NPJ Genom Med2018;3:14
47.
YangQXuFJianAYuHYeTHuW. m6A regulator-mediated methylation modification patterns and tumor microenvironment cell-infiltration characterization in head and neck cancer.Front Cell Dev Biol2022;9:803141
48.
QiuYLiuSChenHTYuCHTengXDYaoHTXuGQ. Upregulation of caveolin-1 and SR-B1 in mice with non-alcoholic fatty liver disease.Hepatobiliary Pancreat Dis Int2013;12:630–6
49.
ZhangYLiangXZhangLWangD. Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer.Sci Rep2021;11:22486
50.
Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019.JAMA Oncol2022;8:420–44
51.
ChaoYLPecotCV. Targeting epigenetics in lung cancer.Cold Spring Harb Perspect Med2021;11:a038000
52.
ZhangLLuQChangC. Epigenetics in health and disease.Adv Exp Med Biol2020;1253:3–55
53.
AsanoT. Drug resistance in cancer therapy and the role of epigenetics.J Nippon Med Sch2020;87:244–51
54.
VillanuevaLÁlvarez-ErricoDEstellerM. The contribution of epigenetics to cancer immunotherapy.Trends Immunol2020;41:676–91
55.
IlangoSPaitalBJayachandranPPadmaPRNirmaladeviR. Epigenetic alterations in cancer.Front Biosci2020;25:1058–109
56.
SheafferKLElliottENKaestnerKH. DNA hypomethylation contributes to genomic instability and intestinal cancer initiation.Cancer Prev Res2016;9:534–46
57.
Mari-AlexandreJDiaz-LagaresAVillalbaMJuanOCrujeirasABCalvoASandovalJ. Translating cancer epigenomics into the clinic: focus on lung cancer.Transl Res2017;189:76–92
58.
CaoGLiHBYinZFlavellRA. Recent advances in dynamic m6A RNA modification.Open Biol2016;6:160003
59.
XuZPengBCaiYWuGHuangJGaoMGuoGZengSGongZYanY. N6-methyladenosine RNA modification in cancer therapeutic resistance: current status and perspectives.Biochem Pharmacol2020;182:114258
60.
ShiJChenXZhangLFangXLiuYZhuXZhangHFanLGuJZhangSSheBHanHYiX. Performance evaluation of SHOX2 and RASSF1A methylation for the aid in diagnosis of lung cancer based on the analysis of FFPE specimen.Front Oncol2020;10:565780
61.
HulbertAJusue-TorresIStarkAChenCRodgersKLeeBGriffinCYangAHuangPWrangleJBelinskySAWangTHYangSCBaylinSBBrockMVHermanJG. Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum.Clin Cancer Res2017;23:1998–2005
62.
LiangWZhaoYHuangWGaoYXuWTaoJYangMLiLPingWShenHFuXChenZLairdPWCaiXFanJBHeJ. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA).Theranostics2019;9:2056–70
63.
NiuXLiuFZhouYZhouZZhouDWangTLiZYeXYuYWengXZhangHYeJLiaoMLiuYChenZLuS. Genome-wide DNA methylation analysis reveals GABBR2 as a novel epigenetic target for EGFR 19 deletion lung adenocarcinoma with induction erlotinib treatment.Clin Cancer Res2017;23:5003–14
64.
ShiehJMTangYAHuFHHuangWJWangYJJenJLiaoSYLuYHYehYLWangTWLinPWangYC. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.Int J Cancer2017;140:2375–86
65.
NehmeERahalZSinjabAKhalilAChamiHNemerGKadaraH. Epigenetic suppression of the T-box subfamily 2 (TBX2) in human non-small cell lung cancer.Int J Mol Sci2019;20:1159
66.
GrasseSLienhardMFreseSKerickMSteinbachAGrimmCHussongMRolffJBeckerMDreherFSchirmerUBoernoSRamischALeschberGTimmermannBGrohéCLüdersHVingronMFichtnerIKleinSOdenthalMBüttnerRLehrachHSültmannHHerwigRSchweigerMR. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.Genome Med2018;10:55
67.
YangLHHanYLiGXuHTJiangGYMiaoYZhangXPZhaoHYXuZFStoeckerMWangEXuKWangEH. Axin gene methylation status correlates with radiosensitivity of lung cancer cells.BMC Cancer2013;13:368
68.
PankovaDJiangYChatzifrangkeskouMVendrellIBuzzelliJRyanABrownCO’NeillE. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.EMBO J2019;38:e100532
69.
SeokYLeeWKParkJYKimDS. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients.Mol Cells2019;42:161–5
70.
ChenYYangLCuiTPacyna-GengelbachMPetersenI. HOPX is methylated and exerts tumour-suppressive function through Ras-induced senescence in human lung cancer.J Pathol2015;235:397–407
71.
LiuWBHanFHuangYSChenHQChenJPWangDDJiangXYinLCaoJLiuJY. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer.Mol Carcinog2019;58:474–87
72.
ZhangCHuangSZhuangHRuanSZhouZHuangKJiFMaZHouBHeX. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.Oncogene2020;39:4507–18
73.
SongPFengLLiJDaiDZhuLWangCLiJLiLZhouQShiRWangXJinH. β-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer.Mol Cancer2020;19:129
74.
DuCLvCFengYYuS. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.J Exp Clin Cancer Res2020;39:223
75.
BremnesRMDønnemTAl-SaadSAl-ShibliKAndersenSSireraRCampsCMarinezIBusundLT. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.J Thorac Oncol2011;6:209–17
76.
ZengCHuangWLiYWengH. Roles of METTL3 in cancer: mechanisms and therapeutic targeting.J Hematol Oncol2020;13:117
77.
HanDLiuJChenCDongLLiuYChangRHuangXLiuYWangJDoughertyUBissonnetteMBShenBWeichselbaumRRXuMMHeC. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells.Nature2019;566:270–4
78.
MaZJiJ. N6-methyladenosine (m6A) RNA modification in cancer stem cells.Stem Cells. Epub ahead of print 27 September 2020. DOI: 10.1002/stem.3279.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
